Yeung, M.D., Seung Ho Hur, M.D., Ki Bae Seung, M.D., Tae Hoon Ahn, M.D., Hyuck Moon Kwon, M.D., Perform-Sun Lim, M.D., Seung-Woon Rha, M.D., Myung-Ho Jeong, M.D., Bong-Ki Lee, M.D., Damras Tresukosol, M.D., Guo Sheng Fu, M.D., and Tiong Kiam Ong, M.D. For the Ideal Trial Investigators: Trial of Everolimus-Eluting Stents or Bypass Medical operation for Coronary Disease.. Seung-Jung Recreation area, M.D., Ph.D., Jung-Min Ahn, M.D., Young-Hak Kim, M.D., Duk-Woo Park, M.D., Sung-Cheol Yun, Ph.D., Jong-Adolescent Lee, M.D., Soo-Jin Kang, M.D., Seung-Whan Lee, M.D., Cheol Whan Lee, M.D., Seong-Wook Park, M.D., Suk Jung Choo, M.D., Cheol Hyun Chung, M.D., Jae Won Lee, M.D., David J. Cohen, M.D., Alan C.The Duke team’s prior work recommended that the regulatory proteins beta-arrestin 2, involved with desensitization of receptor indicators normally, is required for normal dopamine-related behavior. They also discovered that prolonged stimulation of D2 receptors leads to inactivation of a regulatory proteins called Akt. Furthermore, they demonstrated, Akt inactivation occurred even more slowly and was taken care of for much longer than other similar biochemical events that had previously been noticed. However, the system behind that inactivation remained unclear.